Form 8-K - Current report:
SEC Accession No. 0001493152-25-029778
Filing Date
2025-12-31
Accepted
2025-12-31 16:00:47
Documents
13
Period of Report
2025-12-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 39975
2 EX-10.1 ex10-1.htm EX-10.1 119868
  Complete submission text file 0001493152-25-029778.txt   350899

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE lixt-20251230.xsd EX-101.SCH 3005
4 XBRL LABEL FILE lixt-20251230_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE lixt-20251230_pre.xml EX-101.PRE 22352
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3227
Mailing Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432
Business Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 251617425
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)